HLA-DQ: A Key Receptor for DC-Ag and Potential Drug Target (P40588)

Target Name: HLA Class II Histocompatibility Antigen, DQ (HLA-DQ)

NCBI ID: P40588

HLA Class II Histocompatibility Antigen, DQ (HLA-DQ)

Other Name(s): HLA-DQ

HLA-DQ: A Key Receptor for DC-Ag and Potential Drug Target

HLA-DQ, also known as HLA-DQ alpha chain, is a subunit of the human major histocompatibility complex (MHC) and is a key receptor for dendritic cell-derived antigens (DC-Ag) in the immune system. HLA-DQ is a 17-kDa glycoprotein that consists of two heavy chains and two light chains. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region.

HLA-DQ is a key receptor for DC-Ag, which are antigens that can stimulate an immune response. These antigens are derived from self-reactive cells, such as dendritic cells, which are responsible for presenting antigens from the body's own cells to the immune system. When a DC-Ag binds to HLA-DQ, it can activate the immune system and induce an immune response.

HLA-DQ is a member of the HLA class II system, which includes MHC class II molecules that are expressed in the major histocompatibility complex (MHC) and CD4+ T cells. The HLA-DQ molecule is expressed in most tissues and cells, including the skin, hair, nails, mouth, lymph nodes, spleen, thymus, and Peyer's patches in the gut.

HLA-DQ has been implicated in a number of immune-related diseases, including autoimmune disorders, cancer, and infectious diseases. For example, HLA-DQ has been implicated in the development of autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis. HLA-DQ has also been shown to be involved in the regulation of cancer progression and the development of certain types of cancer.

In addition to its role in immune regulation, HLA-DQ has also been shown to be involved in the development and progression of certain diseases. For example, studies have shown that HLA-DQ is involved in the development of skin cancer, and that it can also contribute to the development of certain types of cancer, such as melanoma.

As a potential drug target, HLA-DQ has been the focus of research in recent years. Researchers have been interested in identifying small molecules that can interact with HLA-DQ and modulate its activity. This has led to the development of a number of compounds that have been shown to be HLA-DQ antagonists and have the potential to be used in the treatment of immune-related diseases.

One of the most promising HLA-DQ antagonists is a compound called ODN-101, which is a small molecule that binds to HLA-DQ with high affinity. ODN-101 has been shown to block the activity of HLA-DQ and to induce apoptosis (programmed cell death) in HLA-DQ-positive cancer cells.

In addition to its potential as an HLA-DQ antagonist, ODN-101 has also been shown to have other potential therapeutic benefits. For example, it has been shown to be safe and to have a low potential for adverse effects in human clinical trials. Additionally, ODN-101 has been shown to be effective in treating a variety of HLA-DQ-positive diseases, including skin cancer and certain types of cancer.

While ODN-101 is an encouraging example of an HLA-DQ antagonist, there are still many challenges that must be overcome before it can be approved for use in humans. For example, it is not yet clear what the optimal dosage and timing of ODN-101 treatment will be, or how it will be administered in clinical trials. Additionally,

Protein Name: HLA Class II Histocompatibility Antigen, DQ (HLA-DQ)

The "HLA Class II Histocompatibility Antigen, DQ (HLA-DQ) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA Class II Histocompatibility Antigen, DQ (HLA-DQ) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets